Novo Nordisk has withdrawn a press statement on Tresiba, which was issued on Sep. 19, 2019, after the Danish Maritime and Commercial High Court has ruled that it contained misleading marketing, which Novo Nordisk announces on Monday.
Last year's press announcement stated that Novo expected to present improvements in the average blood sugar level and in cases with low blood sugar – known as hypoglycemia – in the company's insulin product Tresiba, compared with the competing drug Toujeo from French pharmaceutical firm Sanofi.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
System Sales Development Consultant - Investment Projects, Merck Millipore 
Strategic Procurement Manager, Direct Spend (Category Manager) 
IRT Manager, Clinical Drug Supply 
Clinical Trial Manager 
Chemist for Incoming Materials in QC Department 
Analytical Coordinator for Analytical Development 
(Senior) Drug Substance Specialist 
Quality System Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Production Director 
Director for innovative pre-clinical testing unit 
Senior Project Manager (GMP - Life Science) 
Account Manager 
2 Sales Representatives and Product Specialists